Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 11/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.40 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30269669 | 1.00 | MAP4K4 (0.47) | MAP4K4GLP1RHDAC1GPR119SUV39H2 | |
| SCHEMBL23928957 | 0.89 | GLP1R (0.46) | GLP1R | |
| SCHEMBL29965773 | 0.88 | GLP1R (0.53) | MAP4K4GLP1RHDAC1GPR119SUV39H2 | |
| SCHEMBL23964357 | 0.87 | GLP1R (0.47) | MAP4K4GLP1RHDAC1GPR119 | |
| SCHEMBL24320732 | 0.87 | GLP1R (0.54) | MAP4K4GLP1R | |
| SCHEMBL22391741 | 0.86 | GPR119 (0.50) | MAP4K4GLP1RGPR119SUV39H2 | |
| SCHEMBL29966317 | 0.83 | GLP1R (0.53) | MAP4K4GLP1RHDAC1GPR119SUV39H2 | |
| SCHEMBL28786496 | 0.83 | GLP1R (0.43) | MAP4K4GLP1RHDAC1GPR119SUV39H2 | |
| SCHEMBL28786493 | 0.83 | GLP1R (0.43) | MAP4K4GLP1RHDAC1GPR119SUV39H2 | |
| SCHEMBL24320310 | 0.82 | NR1H2 (0.47) | MAP4K4HDAC1GPR119SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112566637-B | GLP-1 receptor agonists and uses thereof | 辉瑞公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-112566637-A | GLP-1 receptor agonists and uses thereof | 辉瑞公司 | 2021-03-26 | — | — | CN | disclosed |